Insider Selling: ASP Isotopes (NASDAQ:ASPI) CEO Sells 81,077 Shares of Stock

Key Points

• CEO Paul Elliot Mann sold a total of 162,153 shares of ASP Isotopes for approximately $1.37 million in early September, reducing his ownership in the company by about 0.99%.
• ASP Isotopes' stock price fell 1.5% to $8.37, with an average volume of 1.9 million shares traded, significantly lower than its average of 4.8 million shares.
• The company reported a loss of ($1.03) EPS for the last quarter, missing estimates by ($0.92), and is expected to post a -0.24 EPS for the current fiscal year.

ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) CEO Paul Elliot Mann sold 81,077 shares of the stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $8.39, for a total value of $680,236.03. Following the completion of the sale, the chief executive officer owned 8,084,191 shares of the company's stock, valued at approximately $67,826,362.49. This represents a 0.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Paul Elliot Mann also recently made the following trade(s):

• On Monday, September 8th, Paul Elliot Mann sold 81,076 shares of ASP Isotopes stock. The stock was sold at an average price of $8.53, for a total transaction of $691,578.28.

ASP Isotopes Stock Down 1.5%

Shares of ASPI stock traded down $0.13 during trading hours on Wednesday, hitting $8.37. 1,946,388 shares of the company were exchanged, compared to its average volume of 4,836,301. The stock has a market capitalization of $769.29 million, a price-to-earnings ratio of -13.72 and a beta of 3.35. ASP Isotopes Inc. has a one year low of $2.32 and a one year high of $11.68. The business's 50-day simple moving average is $9.08 and its two-hundred day simple moving average is $7.09. The company has a debt-to-equity ratio of 3.53, a quick ratio of 14.56 and a current ratio of 14.72.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($1.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.92). ASP Isotopes had a negative return on equity of 239.22% and a negative net margin of 2,181.62%.The business had revenue of $1.20 million for the quarter, compared to analyst estimates of $1.60 million. Sell-side analysts predict that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group raised their target price on shares of ASP Isotopes from $8.50 to $11.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $7.75.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Rovida Advisors Inc. acquired a new position in ASP Isotopes during the second quarter valued at approximately $16,148,000. Rovida Investment Management Ltd raised its position in shares of ASP Isotopes by 528.6% in the second quarter. Rovida Investment Management Ltd now owns 2,200,000 shares of the company's stock valued at $16,148,000 after purchasing an additional 1,850,000 shares during the period. Exchange Traded Concepts LLC bought a new position in shares of ASP Isotopes in the second quarter valued at about $9,593,000. AWM Investment Company Inc. grew its stake in shares of ASP Isotopes by 16.0% in the fourth quarter. AWM Investment Company Inc. now owns 4,246,186 shares of the company's stock valued at $19,235,000 after acquiring an additional 586,600 shares in the last quarter. Finally, Invesco Ltd. grew its stake in ASP Isotopes by 2,205.0% during the second quarter. Invesco Ltd. now owns 471,219 shares of the company's stock worth $3,468,000 after buying an additional 450,776 shares in the last quarter. Institutional investors own 16.80% of the company's stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.